Project description DEENESFRITPL 3D organoid culture system for response prediction in breast cancer therapy Breast cancer (BC) has one of the highest mortality rates and high interindividual variability in response to treatment. The resistance to therapy often arises overtime after the first line of treatment. Current in vitro cell and animal models cannot recapitulate human organism complexity and often cannot predict tumour clinical response. Organoids are emerging as a new approach that may overcome these limitations, and the progress in developing in vitro 3D organoid culture systems from primary breast cancer tissues is attracting attention as an emerging tool. The EU-funded BARRICADE project is developing a novel platform to predict BC outcome and response to therapy in a faster and more specific manner by giving preclinical information for future therapy settings. Show the project objective Hide the project objective Objective “BARRICADE” is about an evolutionary platform to predict breast cancer (BC) patients outcome and response to therapy in a faster and specific manner. Breast cancer is one of the leading causes of cancer mortality among women and is characterized by a high interindividual variability in response to cancer treatment, and often resistance to therapy arise over the time or after first line of treatment. For this reason, the therapeutic approach of each patient has to be set up during its management causing some gaps, useless toxicities and a losing of time useful for patient’s cure. In cancer research, cells are usually grown in a monolayer on dishes of polystyrene plastic to perform experiment or toxicity studies. Alternatively, researchers use animal models that are able to mimic a more physiological growth of tumor cells and they take in account also the microenvironmental influences. Unfortunately, animal models do not recapitulate the human complexity, and sometimes they do not predict tumor behaviour and clinical response. For this reason, organoids are emerging as new more complex system that may overcome the limitations of traditional cancer model. “BARRICADE” will contribute to taking BC cancer therapy to beyond state-of-art, developing personalized anticancer therapies and giving useful information for cure setting up. Indeed, progress in developing in vitro 3D organoid culture system using primary human breast cancer tissues have attracted great interest as an emerging tools for precision medicine. BARRICADE will help to overcome some of those barriers by giving preclinical information for future therapy settings. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicineoncologybreast cancermedical and health scienceshealth sciencespersonalized medicine Keywords breast cancer personalized anticancer therapies Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2019 - Individual Fellowships Call for proposal H2020-MSCA-IF-2019 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator PERCUROS BV Net EU contribution € 175 572,48 Address EERBEEKLAAN 42 2573 HT 's-Gravenhage (Den Haag) Netherlands See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region West-Nederland Zuid-Holland Agglomeratie ’s-Gravenhage Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 175 572,48
